Background/Aims: Evaluation of the socioeconomic value of medical intervention and establishment of the resources necessary for clinical practice are important for new developments in medical technology. The aim of this study was to determine the socioeconomic value of on-line hemodiafiltration (HDF). Methods: The subjects were 24 patients who underwent hemodialysis (HD) (9 HDF, 15 HD) for chronic renal failure. A total of 288 dialysis interventions were observed for 4 weeks in three clinics. Cost-effectiveness was evaluated based on quality-adjusted life years (Qaly) and a visual analog scale. Results: EuroQOL-5D (0.776 ± 0.015) and visual analog scale (67.9 ± 1.2) in the HDF group were higher than those in the HD group at baseline. The incremental cost utility ratio for HDF was 641.7 (JPY 10,000/Qaly) based on Qaly (0.776 ± 0.015) and reimbursement for medical fees (JPY 4,982,736 ± 7,852), and was lower than the incremental cost utility ratio for HD. Conclusion: These results suggest that on-line HDF could be cost-effective.

Keywords:
Socioeconomics-based value, Incremental cost-effectiveness ratio, Quality-adjusted life year, Reimbursement for medical fees, Cost-effectiveness
1.
Takura T: Economic evaluation of medical technology, meaning and directionality for systems: aims of social economic assessment guidelines for medical devices (promotion of medical device manufacturing and marketing programs for fast launch on the market and acquiring economic balance). Jpn J Med Instrum 2007;77:836-846.
2.
Takura T: Approach for new value creation in medicine. J Pharm Business 2009;1349:16-25.
3.
Survey of Medical Care Activities in Public Health Insurance. Tokyo, Ministry of Health, Labour and Welfare, 2010.
4.
Guidelines for Appraising Orphan Drugs, NICE, 2006. http://www.nice.org.uk.
5.
Kiberd BA, Jindal KK: Screening to prevent renal failure in insulin-dependent diabetic patients: an economic evaluation. BMJ 1995;16:1595-1599.
6.
Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, Fluck N, MacLeod A, McNamee P, Prescott G, Smith C: Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess 2010;14:1-184.
7.
Maynard A: Developing the healthcare market. Econ J 1991;101:1277-1286.
8.
Takura T, Sawa Y: Medical economics of transplant: economic concepts for future development of organ transplantation. Transplantation 2009;44:60-68.
9.
Kontodimopoulos N, Niakas D: An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. Health Policy 2008;86:85-96.
10.
Schweitzer EJ, Perencevich EN, Philosophe B, Bartlett ST: Estimated benefits of transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection. Am J Transplant 2007;7:1515-1525.
11.
Liem YS, Kock MC, Ijzermans JN, Weimar W, Visser K, Hunink MG: Living renal donors: optimizing the imaging strategy, decision and cost-effectiveness analysis. Radiology 2003;226:53-62.
12.
Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH, Vasoo S, Li SC, Thumboo J: A comparison of the EuroQol-5D and the Health Utilities Index mark 3 in patients with rheumatic disease. J Rheumatol 2003;30:2268-2274.
13.
Gerber AM, Phelps CE: Economic foundations of cost-effectiveness analysis. J Health Econ 1997;16:1-31.
14.
McGregor M. Cost-utility analysis: use QALYs only with great caution. CMAJ 2003;168:433-434. http://www.cmaj.ca/cgi/content/full/168/4/433.
15.
Schweikert B, Hahmann H, Leidl R: Validation of the EuroQol questionnaire in cardiac rehabilitation. Heart 2006;92:62-67.
16.
Takura T: Contact lens treatment and medical economics. J Jpn Contact Lens Soc 2009;3:204-209.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.